Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation

W. Boucher, Joshua M. Stern, V. Kotsinyan, D. Kempuraj, D. Papaliodis, M. S. Cohen, T. C. Theoharides

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: Interstitial cystitis is a sterile bladder inflammatory disease characterized by pelvic pain, urinary urgency and frequency. Nanocrystalline silver has anti-inflammatory properties, prompting us to investigate its effect in experimental bladder inflammation. Materials and Methods: Nanocrystalline silver (0.01%, 0.05%, 0.1%, 0.5% or 1%) or phosphate buffered saline (Invitrogen™) (0.5 ml) was introduced intravesically in Sprague-Dawley female rat (Charles River Laboratories, Wilmington, Massachusetts) bladders for 20 minutes, followed by vehicle or protamine sulfate (10 mg/ml for 30 minutes) and lipopolysaccharide (Sigma®) (2 mg/ml for 45 minutes). Urine was collected throughout for histamine assay. The catheter was removed, the rat was returned to its cage and 4 hours later it was sacrificed. The bladder was harvested, minced and cultured overnight. The medium was collected for tumor necrosis factor-α assay. Results: Mean ± SD total urine histamine increased from 270 ± 190 ng in 4 controls to 842 ± 239 ng after protamine sulfate/lipopolysaccharide and it decreased to 505 ± 187 ng in 6 animals after pretreatment with 1% nanocrystalline silver (p = 0.036). Tumor necrosis factor-α release in explant medium increased from 0.02 ± 0.03 pg/mg in 6 controls to 0.28 ± 0.15 pg/mg in 14 animals after treatment with protamine sulfate/lipopolysaccharide and it decreased to 0.12 ± 0.11 pg/mg in 10 animals pretreated with nanocrystalline silver (p = 0.009). Nanocrystalline silver was not effective at less than 1% and at 1% alone it released 0.05 ± 0.07 pg/mg tumor necrosis factor-α in 7 rats (vs phosphate buffered saline in 6, p = 0.387). Nanocrystalline silver (1%) significantly decreased bladder inflammation and mast cell activation. These effects were apparent even 4 days later. Conclusions: Intravesical administration of nanocrystalline silver (1%) decreased urine histamine, bladder tumor necrosis factor-α and mast cell activation without any toxic effect. This action may be useful for interstitial cystitis.

Original languageEnglish (US)
Pages (from-to)1598-1602
Number of pages5
JournalJournal of Urology
Volume179
Issue number4
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Silver
Urinary Bladder
Inflammation
Protamines
Tumor Necrosis Factor-alpha
Histamine
Interstitial Cystitis
Lipopolysaccharides
Urine
Mast Cells
Phosphates
Urinary Bladder Diseases
Intravesical Administration
Pelvic Pain
Poisons
Rivers
Nanoparticles
Sprague Dawley Rats
Anti-Inflammatory Agents
Catheters

Keywords

  • bladder
  • cystitis
  • inflammation
  • interstitial
  • silver
  • tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Urology

Cite this

Boucher, W., Stern, J. M., Kotsinyan, V., Kempuraj, D., Papaliodis, D., Cohen, M. S., & Theoharides, T. C. (2008). Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation. Journal of Urology, 179(4), 1598-1602. https://doi.org/10.1016/j.juro.2007.11.037

Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation. / Boucher, W.; Stern, Joshua M.; Kotsinyan, V.; Kempuraj, D.; Papaliodis, D.; Cohen, M. S.; Theoharides, T. C.

In: Journal of Urology, Vol. 179, No. 4, 04.2008, p. 1598-1602.

Research output: Contribution to journalArticle

Boucher, W, Stern, JM, Kotsinyan, V, Kempuraj, D, Papaliodis, D, Cohen, MS & Theoharides, TC 2008, 'Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation', Journal of Urology, vol. 179, no. 4, pp. 1598-1602. https://doi.org/10.1016/j.juro.2007.11.037
Boucher, W. ; Stern, Joshua M. ; Kotsinyan, V. ; Kempuraj, D. ; Papaliodis, D. ; Cohen, M. S. ; Theoharides, T. C. / Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation. In: Journal of Urology. 2008 ; Vol. 179, No. 4. pp. 1598-1602.
@article{8fbb9bf95b78469e9068a63674d76860,
title = "Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation",
abstract = "Purpose: Interstitial cystitis is a sterile bladder inflammatory disease characterized by pelvic pain, urinary urgency and frequency. Nanocrystalline silver has anti-inflammatory properties, prompting us to investigate its effect in experimental bladder inflammation. Materials and Methods: Nanocrystalline silver (0.01{\%}, 0.05{\%}, 0.1{\%}, 0.5{\%} or 1{\%}) or phosphate buffered saline (Invitrogen™) (0.5 ml) was introduced intravesically in Sprague-Dawley female rat (Charles River Laboratories, Wilmington, Massachusetts) bladders for 20 minutes, followed by vehicle or protamine sulfate (10 mg/ml for 30 minutes) and lipopolysaccharide (Sigma{\circledR}) (2 mg/ml for 45 minutes). Urine was collected throughout for histamine assay. The catheter was removed, the rat was returned to its cage and 4 hours later it was sacrificed. The bladder was harvested, minced and cultured overnight. The medium was collected for tumor necrosis factor-α assay. Results: Mean ± SD total urine histamine increased from 270 ± 190 ng in 4 controls to 842 ± 239 ng after protamine sulfate/lipopolysaccharide and it decreased to 505 ± 187 ng in 6 animals after pretreatment with 1{\%} nanocrystalline silver (p = 0.036). Tumor necrosis factor-α release in explant medium increased from 0.02 ± 0.03 pg/mg in 6 controls to 0.28 ± 0.15 pg/mg in 14 animals after treatment with protamine sulfate/lipopolysaccharide and it decreased to 0.12 ± 0.11 pg/mg in 10 animals pretreated with nanocrystalline silver (p = 0.009). Nanocrystalline silver was not effective at less than 1{\%} and at 1{\%} alone it released 0.05 ± 0.07 pg/mg tumor necrosis factor-α in 7 rats (vs phosphate buffered saline in 6, p = 0.387). Nanocrystalline silver (1{\%}) significantly decreased bladder inflammation and mast cell activation. These effects were apparent even 4 days later. Conclusions: Intravesical administration of nanocrystalline silver (1{\%}) decreased urine histamine, bladder tumor necrosis factor-α and mast cell activation without any toxic effect. This action may be useful for interstitial cystitis.",
keywords = "bladder, cystitis, inflammation, interstitial, silver, tumor necrosis factor-alpha",
author = "W. Boucher and Stern, {Joshua M.} and V. Kotsinyan and D. Kempuraj and D. Papaliodis and Cohen, {M. S.} and Theoharides, {T. C.}",
year = "2008",
month = "4",
doi = "10.1016/j.juro.2007.11.037",
language = "English (US)",
volume = "179",
pages = "1598--1602",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Intravesical Nanocrystalline Silver Decreases Experimental Bladder Inflammation

AU - Boucher, W.

AU - Stern, Joshua M.

AU - Kotsinyan, V.

AU - Kempuraj, D.

AU - Papaliodis, D.

AU - Cohen, M. S.

AU - Theoharides, T. C.

PY - 2008/4

Y1 - 2008/4

N2 - Purpose: Interstitial cystitis is a sterile bladder inflammatory disease characterized by pelvic pain, urinary urgency and frequency. Nanocrystalline silver has anti-inflammatory properties, prompting us to investigate its effect in experimental bladder inflammation. Materials and Methods: Nanocrystalline silver (0.01%, 0.05%, 0.1%, 0.5% or 1%) or phosphate buffered saline (Invitrogen™) (0.5 ml) was introduced intravesically in Sprague-Dawley female rat (Charles River Laboratories, Wilmington, Massachusetts) bladders for 20 minutes, followed by vehicle or protamine sulfate (10 mg/ml for 30 minutes) and lipopolysaccharide (Sigma®) (2 mg/ml for 45 minutes). Urine was collected throughout for histamine assay. The catheter was removed, the rat was returned to its cage and 4 hours later it was sacrificed. The bladder was harvested, minced and cultured overnight. The medium was collected for tumor necrosis factor-α assay. Results: Mean ± SD total urine histamine increased from 270 ± 190 ng in 4 controls to 842 ± 239 ng after protamine sulfate/lipopolysaccharide and it decreased to 505 ± 187 ng in 6 animals after pretreatment with 1% nanocrystalline silver (p = 0.036). Tumor necrosis factor-α release in explant medium increased from 0.02 ± 0.03 pg/mg in 6 controls to 0.28 ± 0.15 pg/mg in 14 animals after treatment with protamine sulfate/lipopolysaccharide and it decreased to 0.12 ± 0.11 pg/mg in 10 animals pretreated with nanocrystalline silver (p = 0.009). Nanocrystalline silver was not effective at less than 1% and at 1% alone it released 0.05 ± 0.07 pg/mg tumor necrosis factor-α in 7 rats (vs phosphate buffered saline in 6, p = 0.387). Nanocrystalline silver (1%) significantly decreased bladder inflammation and mast cell activation. These effects were apparent even 4 days later. Conclusions: Intravesical administration of nanocrystalline silver (1%) decreased urine histamine, bladder tumor necrosis factor-α and mast cell activation without any toxic effect. This action may be useful for interstitial cystitis.

AB - Purpose: Interstitial cystitis is a sterile bladder inflammatory disease characterized by pelvic pain, urinary urgency and frequency. Nanocrystalline silver has anti-inflammatory properties, prompting us to investigate its effect in experimental bladder inflammation. Materials and Methods: Nanocrystalline silver (0.01%, 0.05%, 0.1%, 0.5% or 1%) or phosphate buffered saline (Invitrogen™) (0.5 ml) was introduced intravesically in Sprague-Dawley female rat (Charles River Laboratories, Wilmington, Massachusetts) bladders for 20 minutes, followed by vehicle or protamine sulfate (10 mg/ml for 30 minutes) and lipopolysaccharide (Sigma®) (2 mg/ml for 45 minutes). Urine was collected throughout for histamine assay. The catheter was removed, the rat was returned to its cage and 4 hours later it was sacrificed. The bladder was harvested, minced and cultured overnight. The medium was collected for tumor necrosis factor-α assay. Results: Mean ± SD total urine histamine increased from 270 ± 190 ng in 4 controls to 842 ± 239 ng after protamine sulfate/lipopolysaccharide and it decreased to 505 ± 187 ng in 6 animals after pretreatment with 1% nanocrystalline silver (p = 0.036). Tumor necrosis factor-α release in explant medium increased from 0.02 ± 0.03 pg/mg in 6 controls to 0.28 ± 0.15 pg/mg in 14 animals after treatment with protamine sulfate/lipopolysaccharide and it decreased to 0.12 ± 0.11 pg/mg in 10 animals pretreated with nanocrystalline silver (p = 0.009). Nanocrystalline silver was not effective at less than 1% and at 1% alone it released 0.05 ± 0.07 pg/mg tumor necrosis factor-α in 7 rats (vs phosphate buffered saline in 6, p = 0.387). Nanocrystalline silver (1%) significantly decreased bladder inflammation and mast cell activation. These effects were apparent even 4 days later. Conclusions: Intravesical administration of nanocrystalline silver (1%) decreased urine histamine, bladder tumor necrosis factor-α and mast cell activation without any toxic effect. This action may be useful for interstitial cystitis.

KW - bladder

KW - cystitis

KW - inflammation

KW - interstitial

KW - silver

KW - tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=40849106160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849106160&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.11.037

DO - 10.1016/j.juro.2007.11.037

M3 - Article

C2 - 18295255

AN - SCOPUS:40849106160

VL - 179

SP - 1598

EP - 1602

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -